Analyst Price Target is $11.25
▲ +465.33% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Beyond Air in the last 3 months. The average price target is $11.25, with a high forecast of $15.00 and a low forecast of $10.00. The average price target represents a 465.33% upside from the last price of $1.99.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Beyond Air. This Buy consensus rating has held steady for over two years.
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.